MALVERN, PA — MAXONA Pharmaceuticals has officially emerged from stealth mode, announcing the successful completion of its U.S. Phase 1 clinical trials for MAX-001, a groundbreaking non-opioid, non-NSAID oral therapy designed to treat acute and chronic pain. This first-to-market New Molecular Entity (NME) aims to provide effective pain relief without the side effects commonly associated with NSAIDs or the addiction risks of opioids.
Founded by President and CEO Shawn Fatholahi, MAXONA Pharmaceuticals is committed to addressing the nation’s opioid crisis by pioneering safer alternatives for pain management. After seeing the devastating impact of opioid addiction firsthand, Fatholahi made it his mission to develop therapies that offer patients effective relief without risking dependency. MAX-001 is powered by nefopam, an active ingredient proven effective in managing pain through hundreds of global studies and already used in 23 countries, including the U.K. and France.
“We are very pleased to reach this important milestone in the history of MAXONA Pharmaceuticals,” said Fatholahi. “Over the past few years, we’ve assembled a world-class team to advance MAX-001 and bring it to the U.S. healthcare market. This therapy represents a much-needed solution for patients seeking safe, effective pain relief.”
The MAXONA leadership team includes industry veterans with deep expertise in neuroscience, clinical development, pharmacology, and drug formulation. Highlights of the team include Chief Financial Officer Richard Brand, a seasoned financial leader with a proven track record, and Senior Medical Advisor Dr. Roy Freeman of Harvard Medical School, a globally recognized expert in neuropathic pain research and clinical trial design. Their combined expertise positions MAXONA to redefine pain management standards.
With a clear focus on innovation, MAXONA plans to expand its pipeline beyond MAX-001, leveraging its intellectual property and research capabilities to develop additional patient-centric therapies. Following its completion of an eight-figure Series A round in 2021 and a recently closed Series B round, the company is well-capitalized to advance its goals.
Looking ahead, MAXONA states that it remains steadfast in its commitment to transforming pain management through cutting-edge science and compassionate care. The completion of Phase 1 trials for MAX-001 is a key step in its mission to offer safer, more effective treatment options for patients in need.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.